Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 104

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 104
---
 to resist infection by activating the body’s immune system to better and more rapidly respond to pathogen exposure. Preclinical studies in a burn model have shown that systemic administration of MPLA (a bacterially derived mixture of PHAD -likemolecules) post -burnresults in a significantly augmented immune response leading to significantly reduced duration and severity of infection following pseudomonas challenge. Preclinical studies Preclinical studies in a burn model have shown that systemic administration of MPLA (a bacterially derived mixture of PHAD -likemolecules) post -burnresults in a significantly augmented immune response leading to significantly reduced duration and severity of infection following pseudomonas challenge. Figure 13: Reduced Plasma Lactate, Reduced Msofa Score, and Reduced Lung P. Aeruginosa Counts in Response to Pre -Treatment With MPLA in a Sheep Burn Model. (Fukuda 2020) 67 Sheep underwent 20% TBSA cutaneous burn at time 0 followed by vehicle or MPLA (2.5 μg/kg) infusion at 24 hours after burn injury. P. aeruginosawas instilled into the lungs at 48 hours after burn injury The figure shows numbers of the bacteria in lung culture (at 24 hours after P. aeruginosainfection). Open circles represent MPLA preconditioned treatment group animals. Closed circles represent control group. The animal numbers are n=6. Data are expressed as mean ± SEM (* p < 0.05 vs. control). Panel A shows significantly lower plasma lactate concentration in treated vs untreated animals. Panel B shows significantly improved modified sheep Sequential Organ Failure Assessment (mSOFA) score for treated animals vs untreated. Panel C shows significantly less bacterial counts in lung culture (at 24h after P aeruginosa infection) in treated animals vs. untreated. Competition The biopharmaceutical industry is intensely competitive and subject to rapid innovation and significant technological advancements. We believe the key competitive factors that will affect the development and commercial success of our Gemini based programs and any future Program Product candidates are efficacy, safety and tolerability profile, reliability, convenience of dosing, price, the level of generic competition, and reimbursement. Our competitors include multinational pharmaceutical companies, specialized biotechnology companies, universities, and other research institutions. A number of biotechnology and pharmaceutical companies are pursuing the development or marketing of pharmaceuticals that target the same diseases that we are targeting. Smaller or earlier -stagecompanies may also prove to be significant competitors, particularly through collaborative arrangements with large